Suchergebnisse - "Petrylak, D P"

PubPharm (53)

1

TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors : updated safety and efficacy outcomes

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Loriot, Y. | Petrylak, D. | Rezazadeh Kalebasty, A. | +16

2

EV-301 long-term outcomes : 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Rosenberg, J. | Powles, T. | Sonpavde, G. | +11

3

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma : results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2023

von Balar, A. | Castellano, D. | Grivas, P. | +17

4

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide

enthalten in: ESMO open | 2021

von Petrylak, D. | Vaishampayan, U. | Patel, K. | +10

5

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Halabi, S. | Dutta, S. | Tangen, C. | +15

CommentIn: Ann Oncol. 2020 Jul;31(7):829. - PMID 32446817

6

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer : results of >2 years of follow-up

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Fradet, Y. | Bellmunt, J. | Vaughn, D. | +17

CommentIn: Transl Androl Urol. 2019 Oct;8(5):409-413. - PMID 31807417

7

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma : post-progression outcomes from the phase II IMvigor210 study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Necchi, A. | Joseph, R. | Loriot, Y. | +9

8

Borealis-1 : a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Bellmunt, J. | Eigl, B. | Senkus, E. | +12

9

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2017

von Massard, C. | Mateo, J. | Loriot, Y. | +11

CommentIn: Ann Oncol. 2017 Mar 1;28(3):668. - PMID 28426121

10

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

enthalten in: Annals of oncology | 2016

von Massard, C. | Mateo, J. | Loriot, Y. | +11

1
2
3
4
5
6
Nächster »
[6]